Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Akero Therapeutics, Inc. (AKRO)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Mar-31-23Dec-31-22Jun-30-22Mar-31-22Dec-31-21Sep-30-21Jun-30-21
   10-Q10-Q8-K10-Q10-Q10-K10-Q10-Q
Operating expenses:          
Research and development  28.021.8 21.420.527.719.524.0
General and administrative  7.67.07.16.25.54.74.95.0
    Total operating expenses  35.628.850.827.626.132.424.429.0
Loss from operations  -35.6-28.8-25.4-27.6-26.1-32.4-24.4-29.0
Interest expense  -0.9-0.5-0.4-0.1    
Other income, net  5.43.4 0.20.00.00.00.0
    Net loss  -31.1-25.8-23.1-27.4-26.0-32.4-24.3-28.9
Net unrealized (loss) gain on marketable securities  -0.3  0.0    
    Comprehensive loss  -31.4-25.8-23.0-27.4-26.0-32.4-24.3-28.9
   
Net loss per share, basic  ($0.60)($0.55)($0.49)($0.77)($0.74)($0.93)($0.70)($0.83)
Net loss per share, diluted  ($0.60)($0.55)($0.49)($0.77)($0.74)($0.93)($0.70)($0.83)
   
Weighted-average number of shares used in computing net loss per common share, basic  51.946.946.835.435.034.834.934.8
Weighted-average number of shares used in computing net loss per common share, diluted  51.946.946.835.435.0  34.8

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy